Section of Endocrinology, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena Siena, Italy.
Front Endocrinol (Lausanne). 2011 Dec 16;2:94. doi: 10.3389/fendo.2011.00094. eCollection 2011.
Recent findings showed the presence of a reciprocal relationship between thyroid hormones and ghrelin, although the exact mechanism is not known.
Our study is addressed to evaluate the effect of acute exogenous rhTSH administration on serum ghrelin levels in athyreotic patients on replacement l-thyroxine therapy. The study group included 50 patients (16 males and 34 females) submitted to total thyroidectomy and 131-iodine remnant ablation for differentiated thyroid cancer on l-thyroxine therapy. Mean age was 47.5 ± 16.5 years and mean BMI was 25.6 ± 5.01 kg/m(2). rhTSH was administrated at the dosage of 0.9 mg i.m. once daily for two consecutive days. Blood samples were taken between 08.00 and 09.00 after a overnight fasting for measurement of TSH, FT3, FT4, and ghrelin before the first administration of rhTSH and for measurement of TSH and ghrelin 24, 48, 72, and 96 h after the first administration of rhTSH.
Mean ± SD values of basal TSH were 0.54 ± 0.77 μU/ml without significant difference between females and males. As expected, after rhTSH administration TSH concentrations increased at 24 and 48 h with peak TSH values ranging from 20.20 to 313 μU/ml (mean ± SD 98.4 ± 66.7 μU/ml). Mean ± SD values of basal ghrelin were 1085 ± 373 pg/ml without significant difference between males and females. After rhTSH administration ghrelin concentrations decreased significantly (p < 0.01) at 24 h (mean ± SD 934 ± 314 pg/ml p < 0.01) and returned to pre-treatment levels at 96 h.
Our study demonstrates that acute exogenous TSH administration has a suppressive effect on ghrelin secretion independent from changes in thyroid status.
评估促甲状腺激素（rhTSH）对甲状腺功能减退症患者在接受外源性 l-甲状腺素替代治疗时的血清 ghrelin 水平的影响。
研究组纳入了 50 例（男 16 例，女 34 例）接受全甲状腺切除术和 131-碘残留消融术的分化型甲状腺癌患者，这些患者在 l-甲状腺素治疗期间，血清促甲状腺激素（TSH）水平低于正常范围。患者的平均年龄为 47.5±16.5 岁，平均 BMI 为 25.6±5.01kg/m2。rhTSH 以 0.9mg/次的剂量肌内注射，每天 1 次，连续 2 天。在第 1 天 rhTSH 治疗前、第 1 天 rhTSH 治疗后 24、48、72 和 96 小时，采集 08:00 至 09:00 之间禁食过夜后的血液样本，用于测量 TSH、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）和 ghrelin。
女性和男性患者的基础 TSH 平均值±标准差分别为 0.54±0.77μU/ml，无显著差异。与预期结果一致，rhTSH 治疗后，TSH 浓度在 24 和 48 小时升高，峰值 TSH 值范围为 20.20-313μU/ml（平均±标准差 98.4±66.7μU/ml）。女性和男性患者的基础 ghrelin 平均值±标准差分别为 1085±373pg/ml，无显著差异。rhTSH 治疗后，ghrelin 浓度在 24 小时显著下降（平均±标准差 934±314pg/ml，p<0.01），并在 96 小时恢复至治疗前水平。
本研究表明，急性外源性 TSH 给药对 ghrelin 分泌具有抑制作用，这种作用独立于甲状腺状态的变化。
